H7HLAII DNA Influenza Vaccine (H7N9vax-1)

• ClinicalTrials.gov Identifier: NCT06046092
• Recruitment Status: Recruiting
• First Posted: September 21, 2023
• Last Update Posted: September 22, 2023
• Sponsor: Oslo University Hospital
• Information provided by (Responsible Party): Gunnveig Grødeland, Oslo University Hospital

Study Description

Brief Summary:

The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules, for prophylaxis of pandemic H7N9 influenza infection in healthy volunteers.

Condition or disease	Intervention/treatment	Phase
Influenza A; Pandemic Influenza	Biological: H7HLAII	Phase 1

Detailed Description:

H7HLAII is a DNA vaccine that could remedy the current challenges of slow production for conventional influenza vaccines. The prolonged production time of current influenza vaccines has as a consequence that circulating influenza strains often have drifted significantly from the vaccine included strains, and as such reducing vaccine efficacy. The rapid production enabled by the DNA format could enhance efficacy of seasonal influenza vaccines, but is particularly well suited for prophylaxis against an emerging influenza pandemic.

The only vaccine format that can presently be produced and deployed within 2-3 months is DNA. However, DNA vaccines are typically hampered by low immunogenicity. To surpass this challenge, H7HLAII genetically links the influenza H7 HA to a targeting unit that steers the produced vaccine proteins to HLA class II expressing antigen presenting cells (APC). Previously, this strategy has been shown to increase immunogenicity after vaccination in mice, ferrets, pigs, and rhesus macaques, with a particular strength in antibody induction. Of note, antibodies represent a correlate of protection against influenza, as well as most other infectious diseases. It has also been shown that H7HLAII protected immunized ferrets against a homologous H7N9 strain, and with no safety concerns after toxicity testing in guinea pigs.

H7HLAII is designed to induce strong antibody responses against a specific strain of H7N9 influenza. At present, there are several strains of H7N9 that cause concern for future pandemic emergences, in that periodic zoonotic transmissions are observed in Asia. To date, H7N9 viruses do not have the ability to transmit between humans, but the high mortality rates observed after zoonotic transmissions dictates that society ought to be ready for future emergences. H7HLAII is designed to enable rapid exchange of antigen, allowing for accommodation of any HA into the vaccine construct. As such, the strategy could be of great importance for global prophylactic prevention.

Although a pandemic situation might opt for rapid testing, this trial is planned as a cautious phase I trial with healthy volunteers. It should be noted that the safety aspects for a number of DNA vaccines has been good during clinical testing over the past decade, and the first DNA vaccine was recently licensed for human use.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 27 participants
• Allocation: N/A
• Intervention Model: Sequential Assignment
• Intervention Model Description: Open label, single arm dose escalation phase I trial
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: An Open Label, Dose Escalation Phase I Trial to Assess Safety and Immunogenicity of the H7HLAII DNA Vaccine, Encoding Influenza Hemagglutinin H7 Directed to HLA Class II, for Prophylaxis of Pandemic Influenza Infection in Healthy Volunteers
• Actual Study Start Date: July 15, 2023
• Estimated Primary Completion Date: December 31, 2024
• Estimated Study Completion Date: December 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Vaccinated; Participants will be allocated to one of 3 dose groups, each receiving two intradermal (i.d.) vaccinations with 0.12 mg, 0.60 mg, or 3.00 mg of H7HLAII, respectively.	Biological: H7HLAII; DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules

Outcome Measures

Primary Outcome Measures :

1. Solicited adverse events following vaccination [ Time Frame: 10 days ]
   Solicited injection site reactions: Redness, Swelling, Pain, Erythema, and Induration; Solicited systemic reactions: Fever, Sweating, Chill, Nausea, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, and Respiratory symptoms.
2. Abnormalities in physical examination, vital signs, and clinical laboratory tests [ Time Frame: 6 months ]
   Number of participants with aberrant results.

Secondary Outcome Measures :

1. Changes in virus neutralization assay titres relative to baseline [ Time Frame: 6 months ]
   geometric mean titres
2. Changes in anti-H7 antibody levels relative to baseline [ Time Frame: 6 months ]
   seroconversion rates

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy subjects, as concluded from the medical history, physical examination test including normal vital signs, and clinical judgment, without the need for medication.
• For women with childbearing potential (WOCBP), defined as fertile following menarche and until becoming post-menopausal (i.e. no menses for 12 months without an alternative medical cause) unless permanently sterile by hysterectomy, bilateral salpingectomy and bilateral oophorectomy: Must use a highly effective contraceptive measures (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination), and a negative urine pregnancy test before administration of each dose of vaccine. Must agree to not donate eggs during the study and the first three months after their last study visit.
• Able to understand and willing to sign the Informed Consent Form (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
• Subjects able to understand and comply with the study protocol, including being able to attend the scheduled visits.

Exclusion Criteria:

• Medical Conditions

  1. Ongoing or recent (< 2 weeks) intercurrent febrile condition
  2. Previous reports of autoimmune disease
  3. Concurrent chronic active viral hepatitis B or C or HIV
  4. BMI>30
  5. Persons with a history of anaphylaxis or serious reactions to a prior vaccination
  6. Persons with known hypersensitivity to any of the vaccine components
  7. Persons who have had a temperature >38 °C during the previous 72 hours
  8. Persons who have had an acute respiratory infection during the last 7 days
  9. Persons who have abnormal electrocardiogram (ECG)
  10. Women who are pregnant or breast-feeding (women of child-bearing potential must have a negative pregnancy test at screening)
  11. Have received any vaccination within the last month
• Prior/Concomitant Therapy 12. Currently taking anti-inflammatory or immunosuppressive drugs 13. Currently taking antibiotics, steroids, phenytoin, chemotherapy, or other immunosuppressive drugs
• Prior/Concurrent Clinical Study Experience 14. Persons who have participated in another clinical trial during the last month
• Diagnostic assessments 15. Abnormal values of the hematologic and clinical chemistry parameters, as judged by the Investigator, including creatinine, AST, ALT (SGPT), bilirubin and alkaline phosphatase values above normal reference values 16. Positive autoantibodies (anti-nuclear antigens, rheumatoid factor) 17. Serum IgG and IgM lower or higher than the normal reference levels 18. Positive serology tests for hepatitis B or C with detectable hepatitis B HBsAg or DNA, or hepatitis C RNA 19. Positive HIV serology test

Contacts and Locations

Contacts

Contact: Gunnveig Grødeland, PhD; 47 41667705; Gunnveig.Grodeland@medisin.uio.no

Contact: Dag Kvale, MD/PhD; +4795200709; Dag.Kvale@medisin.uio.no

Locations

Norway

Oslo University Hospital; Recruiting

Oslo, Norway, 0372

Contact: Gunnveig Grødeland, PhD 4741667704 gunnveig.grodeland@medisin.uio.no

Contact: Dag Kvale, MD/PhD +4795200709 Dag.Kvale@medisin.uio.no

Sponsors and Collaborators

Oslo University Hospital

Investigators

• Principal Investigator: Dag Kvale, MSc/PhD; Oslo University Hospital

More Information

Publications:

Grodeland G, Fredriksen AB, Loset GA, Vikse E, Fugger L, Bogen B. Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination. J Immunol. 2016 Nov 1;197(9):3575-3585. doi: 10.4049/jimmunol.1600893. Epub 2016 Sep 26.

• Responsible Party: Gunnveig Grødeland, Coordinating Investigator, Oslo University Hospital
• ClinicalTrials.gov Identifier: NCT06046092
• Other Study ID Numbers: 2022-500706-18-01
• First Posted: September 21, 2023
• Last Update Posted: September 22, 2023
• Last Verified: September 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Influenza, Human; Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases